List view / Grid view

Dr Rob Holgate (Research Manager - Abzena)

 

article

Why most T-cell engagers fail – and how to fix it

Bispecific T-cell engagers are advancing fast - but complexity still…

8 August 2025 | By , ,

Bispecific T-cell engagers are advancing fast - but complexity still slows development. This article explores how data-driven, platform-based strategies are helping overcome design and manufacturing hurdles to bring these next-gen therapies to patients faster.